Medical Device Market Access for Thailand, Indonesia, and the Philippines

The medical device markets of Thailand, Indonesia, and the Philippines continue to expand as Southeast Asia’s healthcare ecosystem evolves and demand for advanced medical technologies increases. Rising healthcare investment, expanding hospital infrastructure, and policy reforms across the region are attracting growing interest from international medical device manufacturers.

For companies evaluating entry into ASEAN markets, understanding how these jurisdictions differ in terms of healthcare drivers, regulatory frameworks, and administrative costs is an important first step in developing a practical market strategy.

Continue reading below for a market overview of Thailand, Indonesia, and the Philippines, or contact Cisema for expert guidance on regulatory strategy and medical device market entry across these ASEAN jurisdictions.

Thailand: Established Medical Tourism and Healthcare Innovation Agenda

Thailand is ranked among the top five medical tourism destinations globally, with over 3.5 million foreign patients annually, supported by private hospital excellence and international care standards.

According to World Journal of Advanced Research and Reviews, Thailand remains a top destination for global patients. The government’s Thailand Board of Investment promotes healthcare innovation hubs under the “Thailand 4.0” strategy, enhancing infrastructure for medical devices and digital health systems.

To support this evaluation process, regulatory advisory groups often assist manufacturers in clarifying submission strategies and identifying potential documentation gaps. Within this early planning phase, Cisema provides regulatory intelligence, classification guidance, and feasibility analysis aligned with Thai FDA procedures.

While Thailand offers a well-developed healthcare sector and a relatively mature regulatory framework, other ASEAN markets present different types of opportunities — particularly those driven by population scale and expanding public healthcare coverage. This dynamic becomes particularly evident when examining Indonesia.

Indonesia: Population Scale and Insurance-Driven Procurement Growth

Indonesia is the fourth most populous country in the world, with a population exceeding 277 million. According to the World Bank, the population surge is matched by increasing healthcare demand. Its healthcare system is experiencing significant growth, driven by an expanding healthcare infrastructure and an increasing focus on improving patient outcomes.

According to Statista, the medical device market is projected to reach approximately USD 3.51 billion by 2030, with an annual growth rate of 9.18% during the period from 2025 to 2030. Among the segments, cardiology devices are anticipated to be the largest, with a projected market volume of USD 336.47 million.

In this context, consulting partners such as Cisema support manufacturers by providing country-specific regulatory guidance, dossier planning, and feasibility analysis aligned with Indonesian regulatory procedures.

While Indonesia’s market opportunity is largely driven by population scale, other ASEAN markets offer different advantages. The Philippines, for example, combines steady healthcare expansion with a regulatory environment that is comparatively aligned with international frameworks.

Philippines: Universal Health Coverage and Regulatory Alignment

The Philippines offers a highly accessible regulatory environment with strong alignment to CE Mark and US FDA frameworks. Regulatory reforms such as FDA Circular No. 2021-001A, which streamlines registration by accepting prior approvals from reference markets and aligns submissions with the ASEAN Common Submission Dossier Template (CSDT), support ASEAN technical harmonization.

The market is expected to grow at a compound annual growth rate (CAGR) of 9.66%, reaching approximately US$1.16 billion by 2030. This growth is driven by rising demand for advanced imaging technologies to enhance diagnostic capabilities and support healthcare modernization efforts. For more detailed insights, see Statista.

During this early planning stage, manufacturers frequently collaborate with regulatory advisory partners such as Cisema, which provides classification review, regulatory intelligence, and guidance on ASEAN CSDT-aligned submissions for the Philippine FDA.

Market Comparison Snapshot

Medical Device Application and Licensing Fee Comparison

‍
* Thailand, Indonesia and Philippines: Fees are indicative and may vary due to product category or exchange rates.

Final Thoughts

For international medical device manufacturers, expanding into ASEAN markets requires careful consideration of both commercial opportunity and regulatory readiness. Thailand, Indonesia, and the Philippines each present distinct advantages within the region’s healthcare landscape. Thailand offers a mature ecosystem supported by medical tourism and advanced private hospitals, Indonesia provides significant growth potential driven by population scale and expanding healthcare infrastructure, and the Philippines benefits from regulatory frameworks that increasingly align with international standards.

However, each jurisdiction also operates under its own regulatory authority, classification rules, and documentation requirements. For manufacturers evaluating these markets simultaneously, early feasibility assessment can clarify registration pathways, identify potential documentation gaps, and establish realistic approval timelines before formal submissions begin.

In this context, regulatory advisory partners such as Cisema help manufacturers navigate these early planning stages by providing regulatory intelligence, classification guidance, feasibility analysis, and support with ASEAN CSDT-aligned documentation.

For medical device companies preparing to enter Thailand, Indonesia, or the Philippines, contact Cisema today to discuss their regulatory strategy and begin planning a structured pathway to market entry.

Further Information

To learn more or begin your feasibility evaluation, visit our country-specific service pages:

• Thailand
• Indonesia
• Philippines

If you're a medical device manufacturer with questions about regulatory strategy, timelines, or ASEAN alignment, contact Cisema for tailored insights and expert support.

About the Author: Shouzheng Tan

Shouzheng Tan is Vice President of Southeast Asia at Cisema, based in Penang, Malaysia. He brings more than a decade of experience in the medical device industry, specializing in regulatory registration and market access across Southeast Asia. In his role, he works closely with overseas manufacturers to develop and implement effective regulatory strategies for medical devices throughout the region, including key markets such as Malaysia. His expertise is complemented by working knowledge of quality management systems, allowing him to support clients across both regulatory and compliance requirements.